New Delhi [India], October 14 (ANI): In a significant indigenous boost for the Indian Air Force pilots, the Defence Research and Development Organisation (DRDO) is going to extend the range of the ...

Autonomy start-up Shield AI is expanding its tactical portfolio to include jet-powered aircraft. The San Diego-headquartered firm on 22 October revealed a new vertical take-off and landing ...

Few would disagree that cardio, also called aerobic exercise, is good for your health. Of the 10 most common chronic diseases, seven are "favorably influenced by regular physical activity," according ...

Apple's software engineers continue to internally test iOS 26.0.2, according to MacRumors logs, which have been a reliable indicator of upcoming iOS versions. iOS 26.0.2 will be a minor update that ...

Range Rover is one of the best known automotive brands in the world, and the company's SUVs are easy to identify as the styling never changes all that much. To keep things fresh though, Range Rover ...

We just set out to see which NERF Loadout blasters deliver, and how to build the perfect setup for you and your squad. To find out, we turned Hypebeast HQ into a test arena and filmed an office ...

Hedge-fund billionaire Paul Tudor Jones would like to see the Federal Reserve lower rates to a range of 2.5%-2.75% next year. In an interview with Bloomberg, Jones said he expects the new Fed chair, ...

The MarketWatch News Department was not involved in the creation of this content. Latest contract extends multi-year SRR partnership, bringing Skydio's FY25 program support to $12.3M as Army advances ...

Latest contract extends multi-year SRR partnership, bringing Skydio's FY25 program support to $12.3M as Army advances tactical ISR capabilities X10D, part of the U.S. Department of War's Blue UAS ...

Latest contract extends multi-year SRR partnership, bringing Skydio's FY25 program support to $12.3M as Army advances tactical ISR capabilities SAN MATEO, Calif., Oct. 14, 2025 /PRNewswire/ -- Skydio, ...

Ono Pharmaceutical’s EP4 antagonist hit the primary progression-free survival endpoint in a phase 2 trial in patients with gastric cancer. The biopharma evaluated the Bristol Myers Squibb-partnered ...